-transparent.png){kind=logo}
Monoclonal antibodies directed against two human B cell-restricted antigens, CD19 and CD22, were conjugated to highly purified ricin A chain. These A chain immunotoxins (A-IT) were specifically cytotoxic to Daudi cells and normal human peripheral blood B cells in vitro. The concentration required for 50% inhibition of protein synthesis (IC50) in these cells ranged from 7.5 X 10(-10) M to 4.2 X 10(-9) M. The specific toxicities of these A-ITs for Daudi cells were augmented 2- to 6-fold in the presence of 20mM NH4Cl. These studies demonstrate that A-ITs specific for CD19 and CD22 may be useful in the clinical treatment of B cell malignancies.
Related Publications
R D May, and
E S Vitetta, and
G Moldenhauer, and
B Dörken
October 1983,
Proceedings of the National Academy of Sciences of the United States of America,
R D May, and
E S Vitetta, and
G Moldenhauer, and
B Dörken
January 1982,
Immunological reviews,
R D May, and
E S Vitetta, and
G Moldenhauer, and
B Dörken
February 2003,
Leukemia,
R D May, and
E S Vitetta, and
G Moldenhauer, and
B Dörken
September 1980,
Proceedings of the National Academy of Sciences of the United States of America,
R D May, and
E S Vitetta, and
G Moldenhauer, and
B Dörken
May 1988,
Cancer research,
R D May, and
E S Vitetta, and
G Moldenhauer, and
B Dörken
May 2000,
Leukemia,
R D May, and
E S Vitetta, and
G Moldenhauer, and
B Dörken
January 1984,
Cancer research,
R D May, and
E S Vitetta, and
G Moldenhauer, and
B Dörken
June 1984,
Asian Pacific journal of allergy and immunology,
R D May, and
E S Vitetta, and
G Moldenhauer, and
B Dörken
January 1985,
Cancer drug delivery,
R D May, and
E S Vitetta, and
G Moldenhauer, and
B Dörken
January 1987,
Cancer research,
